Novel compounds, pharmaceutical compositions containing same, and methods of use for same

1 . Compounds of formula I:

wherein

R 1 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR 3 , —C(O)OR 3 , —C(O)R 3 , —CH 2 C(O)OR 3 , —CH 2 C(O)NHR 3 , where R 3 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 2 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X 1 ═NHR 4 , where R 4 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 4 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R 4 group further optionally containing one or more halogen atoms.

2 . The compounds of claim 1 , wherein R 1 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or ═CH 2 .

3 . The compounds of claim 2 , wherein R 1 is CH 3 or ═CH 2 .

4 . The compounds of claim 3 , wherein the compound is selected from the group consisting of:

5 . The compounds of claim 1 , wherein R 4 is —CH 2 C(O)OR 5 or —CH 2 C(O)NHR 5 , where R 5 is H, C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

6 . The compounds of claim 5 , wherein the compound is selected from the group consisting of:

7 . Compounds of formula II:

wherein

R 6 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —C(O)OR 8 , —C(O)R 8 , —CH 2 C(O)OR 8 , —CH 2 C(O)NHR 8 , where R 8 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 7 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X 2 ═NHR 9 , where R 9 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 9 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or ah ether group, the R 9 group further optionally containing one or more halogen atoms;

with the proviso that when R 6 is —CH 3 , and R 7 is n-C 13 H 27 , X 2 is not —NHC 2 H 5 .

8 . The compounds of claim 7 , wherein R 6 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

9 . The compounds of claim 8 , wherein R 6 is —CH 3 .

10 . The compounds of claim 7 , wherein R 9 is —CH 2 C(O)OR 10 or —CH 2 C(O)NHR 10 , where R 10 is H, C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

11 . Compounds of formula IV:

wherein

R 16 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —C(O)OR 18 , —C(O)R 18 , —CH 2 C(O)OR 18 , —CH 2 C(O)NHR 18 , where R 18 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 17 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X 4 ═OR 19 , where R 19 is C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 19 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R 19 group further optionally containing one or more halogen atoms;

with the proviso that when R 16 is —CH 3 and R 19 is —CH 3 , then R 17 is not substituted or unsubstituted phenyl, -nC 3 H 7 , -nC 5 H 11 , -nC 13 H 27 ,

and with the further proviso that when R 16 is H and R 19 is —CH 3 , then R 17 is not substituted or unsubstuted phenyl or —CH 3 , and when R 16 is H and R 19 is —CH 2 CH 3 , then R 17 is not -iC 3 H 7 , or substituted or unsubstituted phenyl.

12 . The compounds of claim 11 , wherein R 16 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13 . The compounds of claim 12 , wherein R 16 is —CH 3 .

14 . The compounds of claim 11 , wherein R 19 is —CH 2 C(O)OR 20 or —CH 2 C(O)NHR 20 , where R 20 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15 . Compounds of formula V:

wherein

R 21 ═C 2 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR 23 , —C(O)OR 23 , —C(O)R 23 , —CH 2 C(O)OR 23 , —CH 2 C(O)NHR 23 , where R 23 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl, except when R 21 is ═CHR 23 , R 23 is not H;

R 22 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R 21 is —COOH, then R 22 is not —CH 3 , -nC 5 H 11 , or C 13 H 27 , and with the further proviso that when R 21 is —CH 2 COOH, then R 22 is not —CH 3 , —CH 2 CH 3 , or -iC 5 H 11 .

16 . The compounds of claim 15 , wherein R 21 is C 2 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17 . The compounds of claim 16 , wherein R 21 is ═CH 2 .

18 . Compounds of formula VI:

wherein:

R 24 ═C 2 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —C(O)OR 26 , —C(O)R 26 , —CH 2 C(O)OR 26 , —CH 2 C(O)NHR 26 , where R 26 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 25 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R 24 is —COOH, then R 25 is not —CH 3 , -nC 5 H 11 , or C 13 H 27 , and with the further proviso that when R 24 is —CH 2 COOH, then R 25 is not CH 3 , —CH 2 CH 3 , or

19 . The compounds of claim 18 , wherein R 21 is C 2 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20 . Compounds of formula VII:

wherein R 27 ═C 3 -C 4 alkyl, C 6 -C 10 alkyl, C 12 alkyl, C 14 alkyl, C 16 -C 20 alkyl.

21 . The compounds of claim 20 , selected from the group consisting of:

22 . A compound of formula VIII:

wherein R 28 is C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, with the proviso that R 28 is not —CH 3 , -nC 3 H 7 , -nC 11 H 23 , or -nC 13 H 27 .

23 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:

R 29 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR 31 , —C(O)OR 31 , —C(O)R 31 , —CH 2 C(O)OR 31 , —CH 2 C(O)NHR 31 , where R 31 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 30 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X 5 ═—OR 32 , or —NHR 32 , where R 32 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 32 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R 32 group further optionally containing one or more halogen atoms;

with the proviso that when R 29 is ═CH 2 , then X 5 is not OH.

24 . The pharmaceutical compositions of claim 23 , wherein R 29 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or ═CH 2 .

25 . The pharmaceutical compositions of claim 24 , wherein R 29 is —CH 3 or ═CH 2 .

26 . The pharmaceutical compositions of claim 23 , wherein R 32 is —CH 2 C(O)OR 33 or —CH 2 C(O)NH 33 , where R 33 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

27 . The pharmaceutical compositions of claim 23 , where R 29 is —C 6 H 13 or —C 8 H 17 .

28 . The pharmaceutical compositions of claim 23 , wherein the compound is selected from the group consisting of:

29 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1 .

30 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7 .

31 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11 .

32 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15 .

33 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18 .

34 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20 .

35 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22 .

36 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III.

wherein

R 11 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR 13 , —C(O)OR 13 , —C(O)R 13 , —CH 2 C(O)OR 13 , —CH 2 C(O)NHR 13 , where R 13 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl;

R 12 ═C 1 -C 20 alkyl cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X 3 ═OR 14 , where R 14 is C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 14 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R 14 group further optionally containing one or more halogen atoms.

37 . The pharmaceutical formulation of claim 36 , wherein R 11 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or ═CH 2 .

38 . The pharmaceutical formulation of claim 37 , wherein R 11 is —CH 3 or ═CH 2 .

39 . The pharmaceutical formulation of claim 36 , wherein R 14 is —CH 2 C(O)OR 15 or —CH 2 C(O)NHR 15 , where R 15 is C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40 . A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

41 . The method of claim 40 , wherein the subject is a human.

42 . The method of claim 40 , wherein the subject is an animal.

43 . The method of claim 41 , wherein the pharmaceutical composition comprises a compound selected from the group consisting of:

44 . The method of claim 42 , wherein the pharmaceutical composition comprises a compound selected from the group consisting of:

45 . A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

46 . The method of claim 45 , wherein the subject is a human.

47 . The method of claim 45 , wherein the subject is an animal.

48 . The method of claim 46 , wherein the pharmaceutical composition comprises a compound selected from the group consisting of:

49 . The method of claim 47 , wherein the pharmaceutical composition comprises a compound selected from the group consisting of:

50 . A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

51 . The method of claim 50 , wherein the subject is a human.

52 . The method of claim 50 , wherein the subject is an animal.

53 . The method of claim 51 , wherein the compound is:

54 . The method of claim 52 , wherein the compound is:

55 . A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

56 . The method of claim 55 , wherein the subject is a human.

57 . The method of claim 55 , wherein the subject is an animal.

58 . A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

59 . The method of claim 58 , wherein the subject is a human.

60 . The method of claim 58 , wherein the subject is an animal.

61 . The method of claim 59 , wherein the compound is selected from the group consisting of:

62 . The method of claim 60 , wherein the compound is selected from the group consisting of:

63 . A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 . The method of claim 63 , wherein the subject is a human.

65 . The method of claim 63 , wherein the subject is an animal.

66 . The method of claim 64 , wherein the compound is selected from the group consisting of:

67 . The method of claim 65 , wherein the compound is selected from the group consisting of: